Epidemiology of gastroesophageal reflux disease in Iran: a systematic review and meta-analysis.
Epidemiology
Gastroesophageal reflux disease
Iran
Meta-analysis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
14 Sep 2020
14 Sep 2020
Historique:
received:
04
03
2020
accepted:
07
08
2020
entrez:
15
9
2020
pubmed:
16
9
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Gastroesophageal reflux disease (GERD), which leads to acid reflux into the esophagus, is a common gastrointestinal disorder. Several studies have shown the prevalence of GERD in Iranian population, but their evidence is contradictory. Therefore, the present study was conducted to investigate the epidemiology of GERD in Iran. The entire steps of this systematic review and meta-analysis were based on the MOOSE protocol, and the results were reported accordance with the PRISMA guideline. This review is registered on PROSPERO (registration number: CRD42020142861). To find potentially relevant published articles, comprehensive search was done on international online databases Scopus, Science Direct, EMBASE, PubMed/Medline, CINAHL, EBSCO, Cochrane Library, Web of Science, Iranian online databases and the Google Scholar search engine in June 2019. Cochran test and I The daily, weekly, monthly, and overall prevalence of GERD symptoms in Iranian population was 5.64% (95%CI [confidence interval]: 3.77-8.35%; N = 66,398), 12.50% (95%CI: 9.63-16.08%; N = 110,388), 18.62% (95%CI: 12.90-26.12%; N = 70,749) and 43.07% (95%CI: 35.00-51.53%; N = 73,189), respectively. The daily, weekly, monthly, and overall prevalence of heartburn in Iranian population was 2.46% (95%CI: 0.93-6.39%; N = 18,774), 9.52% (95%CI: 6.16-14.41%; N = 54,125), 8.19% (95%CI: 2.42-24.30%; N = 19,363) and 23.20% (95%CI: 13.56-36.79%; N = 26,543), respectively. The daily, weekly, monthly, and overall prevalence of regurgitation in Iranian population was 4.00% (95%CI: 1.88-8.32%; N = 18,774), 9.79% (95%CI: 5.99-15.60%; N = 41,140), 13.76% (95%CI: 6.18-44.31%; N = 19,363) and 36.53% (95%CI: 19.30-58.08%; N = 21,174), respectively. The sensitivity analysis for prevalence of all types GERD, heartburn and regurgitation symptoms by removing a study showed that the overall estimate is still robust. The present meta-analysis provides comprehensive and useful information on the epidemiology of GERD in Iran for policy-makers and health care providers. This study showed a high prevalence of GERD in Iran. Therefore, effective measures on GERD-related factors such as lifestyle can be among the health policies of Iran.
Sections du résumé
BACKGROUND
BACKGROUND
Gastroesophageal reflux disease (GERD), which leads to acid reflux into the esophagus, is a common gastrointestinal disorder. Several studies have shown the prevalence of GERD in Iranian population, but their evidence is contradictory. Therefore, the present study was conducted to investigate the epidemiology of GERD in Iran.
METHODS
METHODS
The entire steps of this systematic review and meta-analysis were based on the MOOSE protocol, and the results were reported accordance with the PRISMA guideline. This review is registered on PROSPERO (registration number: CRD42020142861). To find potentially relevant published articles, comprehensive search was done on international online databases Scopus, Science Direct, EMBASE, PubMed/Medline, CINAHL, EBSCO, Cochrane Library, Web of Science, Iranian online databases and the Google Scholar search engine in June 2019. Cochran test and I
RESULTS
RESULTS
The daily, weekly, monthly, and overall prevalence of GERD symptoms in Iranian population was 5.64% (95%CI [confidence interval]: 3.77-8.35%; N = 66,398), 12.50% (95%CI: 9.63-16.08%; N = 110,388), 18.62% (95%CI: 12.90-26.12%; N = 70,749) and 43.07% (95%CI: 35.00-51.53%; N = 73,189), respectively. The daily, weekly, monthly, and overall prevalence of heartburn in Iranian population was 2.46% (95%CI: 0.93-6.39%; N = 18,774), 9.52% (95%CI: 6.16-14.41%; N = 54,125), 8.19% (95%CI: 2.42-24.30%; N = 19,363) and 23.20% (95%CI: 13.56-36.79%; N = 26,543), respectively. The daily, weekly, monthly, and overall prevalence of regurgitation in Iranian population was 4.00% (95%CI: 1.88-8.32%; N = 18,774), 9.79% (95%CI: 5.99-15.60%; N = 41,140), 13.76% (95%CI: 6.18-44.31%; N = 19,363) and 36.53% (95%CI: 19.30-58.08%; N = 21,174), respectively. The sensitivity analysis for prevalence of all types GERD, heartburn and regurgitation symptoms by removing a study showed that the overall estimate is still robust.
CONCLUSION
CONCLUSIONS
The present meta-analysis provides comprehensive and useful information on the epidemiology of GERD in Iran for policy-makers and health care providers. This study showed a high prevalence of GERD in Iran. Therefore, effective measures on GERD-related factors such as lifestyle can be among the health policies of Iran.
Identifiants
pubmed: 32928126
doi: 10.1186/s12876-020-01417-6
pii: 10.1186/s12876-020-01417-6
pmc: PMC7488684
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
297Références
Nat Clin Pract Gastroenterol Hepatol. 2005 Nov;2(11):536-44
pubmed: 16355159
World J Gastroenterol. 2007 Nov 7;13(41):5486-91
pubmed: 17907293
J Gastroenterol Hepatol. 2007 Sep;22(9):1419-22
pubmed: 17716346
Dig Dis Sci. 2018 Nov;63(11):2998-3008
pubmed: 30014224
Turk J Gastroenterol. 2017 May;28(3):179-190
pubmed: 28294953
Gastroenterol Hepatol Bed Bench. 2012 Winter;5(1):54-9
pubmed: 24834199
East Afr J Public Health. 2010 Jun;7(2):196-8
pubmed: 21413604
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Am J Gastroenterol. 2007 Jul;102(7):1353-60
pubmed: 17437507
Aliment Pharmacol Ther. 2003 Jun 1;17(11):1407-13
pubmed: 12786635
Med Decis Making. 2005 Nov-Dec;25(6):646-54
pubmed: 16282215
Am J Gastroenterol. 2008 Nov;103(11):2669-80
pubmed: 19032462
Scand J Gastroenterol. 1998 Jun;33(6):568-71
pubmed: 9669624
Indian J Gastroenterol. 2003 Jul-Aug;22(4):138-9
pubmed: 12962436
J Circadian Rhythms. 2010 Oct 07;8:9
pubmed: 20929565
Int J Mol Epidemiol Genet. 2013 Sep 12;4(3):175-82
pubmed: 24046810
Gut. 2007 Jun;56(6):756-62
pubmed: 17047097
Violence Vict. 2018 Dec;33(6):1148-1175
pubmed: 30573555
Eur J Gastroenterol Hepatol. 2004 May;16(5):495-501
pubmed: 15097043
Indian J Gastroenterol. 2008 Jul-Aug;27(4):153-5
pubmed: 18974465
J Gastroenterol Hepatol. 2011 Jun;26(6):1034-8
pubmed: 21299618
Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943
pubmed: 16928254
Am J Epidemiol. 2005 Dec 1;162(11):1050-61
pubmed: 16221805
Dig Dis Sci. 2011 Jun;56(6):1718-22
pubmed: 21512761
Gut. 2014 Jun;63(6):871-80
pubmed: 23853213
Saudi Med J. 2006 Dec;27(12):1878-81
pubmed: 17143368
Gastroenterology Res. 2017 Apr;10(2):78-83
pubmed: 28496527
Eur J Gastroenterol Hepatol. 2012 Mar;24(3):233-47
pubmed: 22186188
Middle East J Dig Dis. 2012 Jan;4(1):5-15
pubmed: 24829629
World J Gastroenterol. 2009 Feb 28;15(8):961-5
pubmed: 19248195
Aliment Pharmacol Ther. 2008 Jul;28(1):144-53
pubmed: 18410559
Dig Dis Sci. 2009 May;54(5):964-71
pubmed: 19255852
Gastroenterology. 2004 Jun;126(7):1692-9
pubmed: 15188164
Middle East J Dig Dis. 2017 Jul;9(3):129-138
pubmed: 28894514
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
J Clin Gastroenterol. 2008 Apr;42(4):345-50
pubmed: 18277907
Am J Med Sci. 2004 Jan;327(1):1-4
pubmed: 14722388
Int J Prev Med. 2012 Mar;3(Suppl 1):S10-7
pubmed: 22826749
Gut. 2005 May;54(5):710-7
pubmed: 15831922
Aliment Pharmacol Ther. 2002 Oct;16(10):1795-800
pubmed: 12269973
Addict Health. 2013 Summer-Autumn;5(3-4):140-53
pubmed: 24494171
BMC Gastroenterol. 2020 May 6;20(1):138
pubmed: 32375671
BMC Gastroenterol. 2018 Jan 10;18(1):8
pubmed: 29320988
Surg Clin North Am. 2015 Jun;95(3):515-25
pubmed: 25965127
Iran Red Crescent Med J. 2014 Dec 09;16(12):e15832
pubmed: 25763231
J Clin Epidemiol. 2002 Oct;55(10):1041-5
pubmed: 12464381
BMC Public Health. 2018 Sep 21;18(1):1133
pubmed: 30241473
Arch Iran Med. 2007 Jul;10(3):289-94
pubmed: 17604463
Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26
pubmed: 17142109
PLoS One. 2014 Feb 21;9(2):e89256
pubmed: 24586635
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120